Decoction for promoting blood circulation and dispelling wind
Through the use of Huoxue Qufeng Decoction, the problems of postoperative blood stasis, edema and infection in hemodialysis patients were solved, the blood flow of internal fistula was improved, the service life was extended, and the success rate of surgery was improved.
Patent Information
- Application Number
- CN202411376844.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-30
- Publication Date
- 2024-12-13
AI Technical Summary
The prior art is difficult to effectively improve the vascular access function of hemodialysis patients, maintain the patency rate of fistula and prolong the service life, especially the problems of blood stasis, edema and infection after autologous arteriovenous fistula surgery.
Provide a kind of blood-saving and Feng Feng soup, which consists of turtle insects, calcined oysters, vinegar, bupleurum, bupleurum, cumin, cherry blossoms, angelica, white peony, rehmannia, peach kernel, safflower, honeysuckle, forsythia, leucorrhea, and Wangbuli. It is prepared by decocting, soapberry, fritillaria, tangerine peel, banfeng, angelica, angelica, angelica and roasted licorice with thick water. It is used to prevent and treat postoperative blood stasis, edema and infection and improve blood flow.
It significantly reduces the incidence of redness, swelling and exudation after surgery, improves the fistula blood flow and maximum dialysis blood flow within one week after surgery, extends the service life of the fistula, and improves the success rate of the surgery.
Smart Images

Figure BDA0005068897360000041 
Figure BDA0005068897360000042 
Figure BDA0005068897360000043
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of perioperative treatment of arteriovenous fistula surgery, and in particular to a blood-activating and wind-dispelling soup. Background Art
[0002] Vascular access is the lifeline of hemodialysis patients, and the forearm autologous arteriovenous fistula (AVF) is the first choice. AVF often suffers from dysfunction due to various reasons. How to better improve vascular access for hemodialysis patients, improve blood flow, maintain fistula patency, extend service life, and increase success rate is an important issue facing us. Summary of the invention
[0003] The invention aims to provide a blood-activating and wind-dispelling soup.
[0004] To achieve the above object, the present invention provides the following technical solutions:
[0005] A blood-activating and wind-dispelling soup is made by boiling water with earthworm, calcined oyster, vinegar turtle shell, bupleurum, radix trichosanthis, ligusticum chuanxiong, angelica, white peony root, rehmannia root, peach kernel, safflower, honeysuckle, forsythia, smilax glabra, fenugreek, gleditsia sinensis, thunbergia thunbergii, tangerine peel, siler, angelica dahurica, notopterygium wilfordii and roasted licorice.
[0006] Furthermore, the described earthworm 3g, calcined oyster 9g, vinegar turtle shell 9g, bupleurum 6g, root of trichosanthes 6g, chuanxiong 12g, angelica 12g, white peony 12g, prepared rehmannia glutinosa 12g, peach kernel 6g, safflower 6g, honeysuckle 3g, forsythia 6g, smilax glabra 9g, fenugreek 9g, gacaria 5g, thunbergia thunbergii 6g, tangerine peel 6g, siler 9g, angelica dahurica 6g, notopterygium wilfordii 9g and roasted liquorice 6g.
[0007] Furthermore, the concentrated decoction is made into 100 mL.
[0008] Compared with the prior art, the present invention can effectively prevent and treat blood stasis, edema and infection after internal fistula surgery, improve the blood flow of internal fistula and prolong the service life. DETAILED DESCRIPTION
[0009] The technical scheme of the present invention is further described below in conjunction with specific examples. It should be understood that the following examples are only exemplary descriptions and explanations of the present invention, and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0010] Example 1
[0011] Take 3g of Eupolyphaga sinensis, 9g of calcined oyster shell, 9g of vinegar turtle shell, 6g of bupleurum, 6g of Radix Trichosanthis, 12g of Ligusticum chuanxiong, 12g of Angelica sinensis, 12g of White Peony Root, 12g of Rehmannia glutinosa, 6g of Peach Kernel, 6g of Carthamus tinctorius, 3g of Honeysuckle, 6g of Forsythia suspensa, 9g of Rhizoma Cyperi, 9g of Vaccaria segetalis, 5g of Gleditsia sinensis, 6g of Fritillaria thunbergii, 6g of Citrus reticulata, 9g of Saposhnikovia divaricata, 6g of Angelica dahurica, 9g of Notopterygium wilfordii and 6g of roasted Licorice root, add water and boil until 100ml, take it in two doses, 50ml orally each time, twice a day, for 7 consecutive days starting from the day after surgery.
[0012] Clinical trials
[0013] personnel
[0014] 160 patients who underwent autologous arteriovenous fistula surgery were randomly divided into a control group and a treatment group, with 80 cases in each group. Because one patient died less than 3 months after surgery and 3 patients lost contact after being transferred out of the dialysis center, 156 cases were actually enrolled, with 78 cases in the treatment group and 78 cases in the control group.
[0015] When grouping, the main factors affecting the results, such as age, gender, course of disease, type of medication, etc., were considered, and a balance test was performed to ensure comparability between groups.
[0016] Treatment
[0017] Both groups of patients underwent conventional forearm autologous arteriovenous fistula formation; the vascular anastomosis method was end-to-side anastomosis.
[0018] Control group: Routine cephalic vein-radial artery autologous fistula-plasty; end-to-side anastomosis with 7-0 vascular sutures; Class I incision, no antibiotics after surgery; oral diclofenac sodium 75 mg, prn, 1-2 times after surgery; dressing change 3 days after surgery, and then every 3 days, and sutures were removed 14 days after surgery without special circumstances.
[0019] Treatment group: Huoxue Qufeng Decoction was added to the control group, 50 mL was taken orally at a time, twice a day, for 7 consecutive days starting from the day after surgery.
[0020] Observation indicators
[0021] (1) Whether there is any redness, swelling, exudation, or suppuration in the wound within one week after surgery.
[0022] (2) Eight weeks after surgery, color Doppler ultrasound was used to examine the blood flow in the brachial artery on the fistula-operated side, and the difference in mean blood flow between the two groups was compared.
[0023] (3) After the fistula was started, the Japanese NIPRO arteriovenous fistula puncture needle with a tube diameter of 1.6G was used uniformly. The maximum dialysis blood flow that could be achieved during the first three punctures was recorded, and the difference in the average maximum dialysis blood flow between the two groups was compared.
[0024] Note: If the fistula is blocked after surgery and there is no murmur, or if the fistula flow is insufficient due to poor venous dilatation and puncture is not possible after evaluation, if color Doppler ultrasound examination and actual puncture are not performed, the color Doppler ultrasound blood flow and maximum dialysis blood flow are calculated as 0. If color Doppler ultrasound examination and actual puncture are performed, the color Doppler ultrasound blood flow and maximum dialysis blood flow are calculated according to the actual results.
[0025] Statistical methods
[0026] SPSS26.0 statistical software was used for data collation and analysis. If the measurement data did not conform to the normal distribution, the median (upper and lower quartiles) was used to express it, and the Mann-Whitney U test was used for inter-group comparison. The count data were expressed as frequency (percentage), and the chi-square test was used for inter-group comparison. P<0.05 was considered statistically significant.
[0027] Comparison of wound conditions between the two groups within 1 week after surgery
[0028] The chi-square test showed that the incidence of wound redness, swelling and exudation in the treatment group within 1 week after surgery was lower than that in the control group (P<0.05). The results are shown in Table 1 below.
[0029] If the patient's wound presents more than one condition, one case will be recorded for each corresponding condition. (For example, some patients have redness and swelling, so the result record will record one case for each redness and swelling).
[0030] Table 1 Comparison of wound conditions between the two groups within 1 week after surgery
[0031]
[0032] Comparison of fistula blood flow between two groups of patients
[0033] The Mann-Whitney U test showed that the color Doppler ultrasound fistula blood flow in the treatment group was higher than that in the control group, and the difference was statistically significant (P<0.05). The results are shown in Table 2 below.
[0034] Table 2 Comparison of color Doppler ultrasound fistula blood flow between the two groups of patients
[0035]
[0036] Comparison of maximum dialysis blood flow between the two groups
[0037] The Mann-Whitney U test showed that the maximum dialysis blood flow in the treatment group was higher than that in the control group, and the difference was statistically significant (P<0.05). The results are shown in Table 3 below.
[0038] Table 3 Comparison of maximum dialysis blood flow between the two groups of patients
[0039]
[0040] Although the specific implementation modes of the present invention are described above, those skilled in the art should understand that the specific implementation modes described are only illustrative and are not intended to limit the scope of the present invention. Any modifications and changes made by those skilled in the art in accordance with the spirit of the present invention should be included in the scope of protection of the claims of the present invention.
Claims
1. A decoction for promoting blood circulation and dispelling wind, characterized in that: It is made by boiling water with the help of earthworm, calcined oyster, vinegar turtle shell, bupleurum, radix trichosanthis, ligusticum chuanxiong, angelica, white peony root, rehmannia root, peach kernel, safflower, honeysuckle, forsythia, smilax glabra, fenugreek, gleditsia thorn, thunbergia thunbergii, tangerine peel, siler, angelica dahurica, notopterygium and roasted licorice.
2. The decoction for promoting blood circulation and dispelling wind according to claim 1, characterized in that: The described ingredients include 3g of Scolopendra subspinipes, 9g of calcined oyster shell, 9g of vinegar turtle shell, 6g of bupleurum, 6g of Radix Trichosanthis, 12g of Ligusticum chuanxiong, 12g of Angelica sinensis, 12g of White Peony Root, 12g of Rehmannia glutinosa, 6g of peach kernel, 6g of Carthamus tinctorius, 3g of Honeysuckle, 6g of Forsythia suspensa, 9g of Rhizoma Cyperi, 9g of Vaccaria segetalis, 5g of Gleditsia sinensis, 6g of Fritillaria thunbergii, 6g of Citrus reticulatae, 9g of Saposhnikovia divaricatae, 6g of Angelica dahurica, 9g of Notopterygium wilfordii and 6g of roasted Licorice root.
3. The decoction for promoting blood circulation and dispelling wind according to claim 1, characterized in that: The concentrated decoction is made into 100 mL.
